COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

被引：0
|
作者：
El Ouagari, K. [1 ]
Pawar, V [2 ]
Coombs, J. [3 ]
Rubin, J. [2 ]
机构：
[1] Novartis Pharmaceut Canada, Dorval, PQ, Canada
[2] I3 Innovus, Medford, MA USA
[3] Novartis, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [11] Cost-effectiveness analysis of regorafenib for gastrointestinal stromal tumour (GIST) in Germany
    Draexler, K.
    Tamoschus, D.
    Chang, J.
    Ngai, C.
    Madin-Warburton, M.
    Pitcher, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S452 - S452
  • [12] Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany
    David Tamoschus
    Katja Draexler
    Jane Chang
    Christopher Ngai
    Matthew Madin-Warburton
    Ashley Pitcher
    Clinical Drug Investigation, 2017, 37 : 525 - 533
  • [13] Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
    Fulgenzi, Claudia Angela Maria
    Napolitano, Andrea
    Faiella, Eliodoro
    Messina, Laura
    Castiello, Gennaro
    Paternostro, Flavia
    Silletta, Marianna
    Pantano, Francesco
    Tonini, Giuseppe
    Santini, Daniele
    Vincenzi, Bruno
    JOURNAL OF BONE ONCOLOGY, 2022, 34
  • [14] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Freemantle, Nick
    Khalaf, Kristin
    Loveman, Clara
    Stanisic, Sanja
    Gultyaev, Dmitry
    Lister, Johanna
    Drake, Marcus
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 911 - 921
  • [15] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Nick Freemantle
    Kristin Khalaf
    Clara Loveman
    Sanja Stanisic
    Dmitry Gultyaev
    Johanna Lister
    Marcus Drake
    The European Journal of Health Economics, 2016, 17 : 911 - 921
  • [16] COST-EFFECTIVENESS OF SUNITINIB AS SECOND-LINE TREATMENT FOR GASTROINTESTINAL STROMAL TUMOR(GIST) IN CHINA
    Ren, H.
    Zhang, J.
    Dong, P.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [17] Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 163 - 168
  • [18] THE COST-EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC/INOPERABLE GASTROINTESTINAL STROMAL TUMORS IN TURKEY
    Deger, C.
    Telli, F.
    Gunaldi, M.
    Keskin, S.
    Saglam, S.
    Ozdemir, O.
    Sar, C.
    Parali, E.
    Erdal, E.
    Sumer, F.
    Ozel, O.
    Asan, S.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [19] The cost-effectiveness of supportive periodontal care: a global perspective
    Pennington, Mark
    Heasman, Peter
    Gaunt, Francesca
    Guentsch, Arndt
    Ivanovski, Saso
    Imazato, Satoshi
    Rajapakse, Sunethra
    Allen, Edith
    Flemmig, Thomas
    Sanz, Mariano
    Vernazza, Chris
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2011, 38 (06) : 553 - 561
  • [20] Imatinib: Cost-effective in the treatment of gastrointestinal stromal tumors
    Finketstein, Stan N.
    Huse, Daniel M.
    Glendenning, G. A.
    Blanke, Charles D.
    Joensuu, Heikki
    von Mehren, Margaret
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
12345